(Q38024391)

27 August 2017

Acetylcholinesterase inhibitors: a patent review (2008 - present). (English)

1 reference

27 August 2017

Miroslav Pohanka

1

0 references

language of work or name

English

0 references

publication date

6 July 2012

1 reference

Expert Opinion on Therapeutic Patents

27 August 2017

1 reference

27 August 2017

22

1 reference

27 August 2017

8

1 reference

27 August 2017

871-886

1 reference

Localisation of pre- and postsynaptic cholinergic markers in the human brain

27 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinesterases, a target of pharmacology and toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinergic central system, Alzheimer's disease, and anesthetics liaison: a vicious circle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinergic systems mediate action from movement to higher consciousness

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Acetylcholine beyond neurons: the non-neuronal cholinergic system in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cytosolic choline acetyltransferase binds specifically to cholinergic plasma membrane of rat brain synaptosomes to generate membrane-bound enzyme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Synaptic like microvesicles: do they participate in regulated exocytosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The t-SNARE complex: a close up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

SNARE complex regulation by phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Botulinum neurotoxin structure, engineering, and novel cellular trafficking and targeting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

A review of experimental techniques used for the heterologous expression of nicotinic acetylcholine receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Mammalian nicotinic acetylcholine receptors: from structure to function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Alpha7 nicotinic acetylcholine receptor is a target in pharmacology and toxicology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Macrophage-assisted inflammation and pharmacological regulation of the cholinergic anti-inflammatory pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Kinetics of M1 muscarinic receptor and G protein signaling to phospholipase C in living cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Relationship between sequence conservation and three-dimensional structure in a large family of esterases, lipases, and related proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Acetylcholinesterase: how is structure related to function?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Probing Torpedo californica acetylcholinesterase catalytic gorge with two novel bis-functional galanthamine derivatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Anionic subsites of the catalytic center of acetylcholinesterase from Torpedo and from cobra venom

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Flexibility of aromatic residues in the active-site gorge of acetylcholinesterase: X-ray versus molecular dynamics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Targeting acetylcholinesterase to treat neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The adhesion function on acetylcholinesterase is located at the peripheral anionic site

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Are soluble and membrane-bound rat brain acetylcholinesterase different?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The polymorphism of acetylcholinesterase: post-translational processing, quaternary associations and localization

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Organophosphate poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Organophosphates⧸Nerve Agent Poisoning: Mechanism of Action, Diagnosis, Prophylaxis, And Treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Organophosphate poisoning in a 12-day-old infant: case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Atropine maintenance dosage in patients with severe organophosphate pesticide poisoning

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Carbamates with differential mechanism of inhibition toward acetylcholinesterase and butyrylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Aging mechanism of butyrylcholinesterase inhibited by an N-methyl analogue of tabun: implications of the trigonal-bipyramidal transition state rearrangement for the phosphylation or reactivation of cholinesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The developmental neurotoxicity of organophosphorus insecticides: a direct role for the oxon metabolites

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Activated transformations of organophosphorus insecticides in the case of non-AChE inhibitory oxons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Occupational exposure to carbofuran and the incidence of cancer in the Agricultural Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Carbofuran-induced oxidative stress in mammalian brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Comparative genomics: Insecticide resistance in mosquito vectors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Alzheimer's disease and related neurodegenerative disorders: implication and counteracting of melatonin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Modulators of cytoskeletal reorganization in CA1 hippocampal neurons show increased expression in patients at mid-stage Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Tau protein: relevance to Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Acitretin, an enhancer of alpha-secretase expression, crosses the blood-brain barrier and is not eliminated by P-glycoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Which memory system is impaired first in Alzheimer's disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinesterase inhibitors used in the treatment of Alzheimer's disease: the relationship between pharmacological effects and clinical efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Targeting the nicotinic alpha7 acetylcholine receptor to enhance cognition in disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinesterase inhibitors and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Memantine ER, a once-daily formulation for the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Donepezil (E2020): a new acetylcholinesterase inhibitor. Review of its pharmacology, pharmacokinetics, and utility in the treatment of Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

A review of clinical pharmacokinetics and pharmacodynamics of galantamine, a reversible acetylcholinesterase inhibitor for the treatment of Alzheimer's disease, in healthy subjects and patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Three-dimensional structure of a complex of galanthamine (Nivalin) with acetylcholinesterase from Torpedo californica: implications for the design of new anti-Alzheimer drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Galantamine enhances dopaminergic neurotransmission in vivo via allosteric potentiation of nicotinic acetylcholine receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Rivastigmine in the treatment of patients with Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Huperzine A protects isolated rat brain mitochondria against beta-amyloid peptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Huperzine B, a novel acetylcholinesterase inhibitor, attenuates hydrogen peroxide induced injury in PC12 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

[+]-Huperzine A treatment protects against N-methyl-D-aspartate-induced seizure/status epilepticus in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Huperzine a as potential treatment of Alzheimer's disease: an assessment on chemistry, pharmacology, and clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Toxicological scoring of Alzheimer's disease drug huperzine in a guinea pig model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Pharmacokinetics of huperzine A following oral administration to human volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Identification of cytochrome P450 1A2 as enzyme involved in the microsomal metabolism of Huperzine A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Huperzine A from Huperzia species--an ethnopharmacolgical review.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Seasonal phenology and management of Tomarus subtropicus (Coleoptera: Scarabaeidae) in St. Augustinegrass

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Metrifonate alters antioxidant levels and caspase activity in cerebral cortex of Wistar rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Tacrine derivatives and Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Re-evaluation of tacrine hepatotoxicity using gel entrapped hepatocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Structure, function, regulation and polymorphism and the clinical significance of human cytochrome P450 1A2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Changes in readthrough acetylcholinesterase expression modulate amyloid-beta pathology.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Effects of cholinesterase inhibitors on the activities and protein levels of cholinesterases in the cerebrospinal fluid of patients with Alzheimer's disease: a review of recent clinical studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The First Dual ChE/FAAH Inhibitors: New Perspectives for Alzheimer's Disease?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

New tacrine-4-oxo-4H-chromene hybrids as multifunctional agents for the treatment of Alzheimer's disease, with cholinergic, antioxidant, and β-amyloid-reducing properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Tacrine-melatonin hybrids as multifunctional agents for Alzheimer's disease, with cholinergic, antioxidant, and neuroprotective properties

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

5-HT6 receptor antagonists reverse delay-dependent deficits in novel object discrimination by enhancing consolidation--an effect sensitive to NMDA receptor antagonism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Therapeutic options in autoimmune myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Treatment of myasthenia gravis: focus on pyridostigmine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Acetylcholinesterase inhibitors in MG: to be or not to be?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Antisense treatment for myasthenia gravis: experience with monarsen

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

Genetic predisposition to adverse consequences of anti-cholinesterases in 'atypical' BCHE carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543776.2012.701620

10.1517/13543776.2012.701620

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference

PubMed ID

22768972